JP Morgan Chase’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,111
| Closed | -$1.47K | – | 7901 |
|
|
2024
Q3 | $1.47K | Buy |
1,111
+107
| +11% | +$517 | ﹤0.01% | 6673 |
|
|
2024
Q2 | $7.63K | Hold |
1,004
| – | – | ﹤0.01% | 6308 |
|
|
2024
Q1 | $9.04K | Hold |
1,004
| – | – | ﹤0.01% | 6355 |
|
|
2023
Q4 | $10.8K | Hold |
1,004
| – | – | ﹤0.01% | 6384 |
|
|
2023
Q3 | $6.09K | Buy |
1,004
+1,003
| +100,300% | +$7.06K | ﹤0.01% | 6341 |
|
|
2023
Q2 | $9 | Hold |
1
| – | – | ﹤0.01% | 6823 |
|
|
2023
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7382 |
|
|
2022
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 7165 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 6992 |
|
|
2022
Q2 | $0 | Sell |
1
-1,038
| -100% | -$23.1K | ﹤0.01% | 7029 |
|
|
2022
Q1 | $29K | Sell |
1,039
-15
| -1% | -$546 | ﹤0.01% | 5986 |
|
|
2021
Q4 | $48K | Sell |
1,054
-996
| -49% | -$67K | ﹤0.01% | 5965 |
|
|
2021
Q3 | $171K | Buy |
2,050
+1,200
| +141% | +$99.3K | ﹤0.01% | 5315 |
|
|
2021
Q2 | $81K | Buy |
850
+838
| +6,983% | +$99.4K | ﹤0.01% | 5611 |
|
|
2021
Q1 | $2K | Buy |
+12
| New | +$1.59K | ﹤0.01% | 5957 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 6027 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 5873 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 5787 |
|
|
2019
Q4 | – | Sell |
-3
| Closed | – | – | 5954 |
|
|
2019
Q3 | $0 | Buy |
+3
| New | +$307 | ﹤0.01% | 6025 |
|
|
2019
Q2 | – | Sell |
-9
| Closed | -$1K | – | 6081 |
|
|
2019
Q1 | $1K | Sell |
9
-41
| -82% | -$6.12K | ﹤0.01% | 5704 |
|
|
2018
Q4 | $5K | Buy |
50
+42
| +525% | +$8.4K | ﹤0.01% | 5540 |
|
|
2018
Q3 | $2K | Sell |
8
-30
| -79% | -$72K | ﹤0.01% | 5621 |
|
|
2018
Q2 | $82K | Buy |
+38
| New | +$96.4K | ﹤0.01% | 4909 |
|
|
2018
Q1 | – | Sell |
-7
| Closed | -$12K | – | 5690 |
|
|
2017
Q4 | $12K | Sell |
7
-22
| -76% | -$31.9K | ﹤0.01% | 5241 |
|
|
2017
Q3 | $35K | Buy |
+29
| New | +$26.1K | ﹤0.01% | 4543 |
|
Other funds holding ONCT
JP Morgan Chase's ONCT Position: Q4 2024 in Review
JP Morgan Chase sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 1,111 shares — an estimated $1.47K sold.
JP Morgan Chase first reported a position in ONCT in Q3 2017 and held it in 22 quarters. The position peaked at $171K in Q3 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.
- JP Morgan Chase reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- JP Morgan Chase sold 1,111 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $1.47K.
- JP Morgan Chase first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2017 and held it in 22 quarters.
- JP Morgan Chase's Oncternal Therapeutics, Inc. Common Stock position peaked at $171K in Q3 2021.
- 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.